Quantum Biopharma (QNTM) EBIT (2019 - 2026)

Quantum Biopharma has disclosed EBIT across 8 years of filings, most recently posting -$2.3 million for Q2 2026.

• In Q2 2026, EBIT rose 52.74% year-over-year to -$2.3 million; the TTM figure through Jun 2026 stood at -$12.3 million (up 15.23% YoY), while the FY2025 annual figure was -$15.3 million, up 5.17% from the prior year.
• EBIT came in at -$2.3 million for Q2 2026 at Quantum Biopharma, up from -$3.0 million in the prior quarter.
• In the past five years, EBIT ranged from a high of $5.6 million in Q1 2022 to a low of -$10.0 million in Q1 2023.
• Average EBIT over 5 years is -$4.2 million, with a median of -$3.8 million recorded in 2024.
• Year-over-year, EBIT slumped 2265.58% in 2022 and soared 77.33% in 2024.
• Over 5 years, EBIT stood at -$6.7 million in 2022, then slumped by 30.92% to -$8.7 million in 2023, then soared by 76.01% to -$2.1 million in 2024, then declined by 13.48% to -$2.4 million in 2025, then advanced by 3.36% to -$2.3 million in 2026.
• Per Business Quant data, the three most recent EBIT figures were -$2.3 million in Q2 2026, -$3.0 million in Q1 2026, and -$2.4 million in Q4 2025.